1. Schultz SK, Andreasen NC. Schizophrenia. Lancet 1999;353(9162):1425-1430.

2. Abdolmaleky HM, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders: Dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics 2005;5(3):149-160.

3. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004;7(Suppl 1):S1-S5.

4. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: From pathophysiology to treatment. Ann NY Acad Sci 2003;1003:138-158.

5. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(7):1159-1172.

6. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005;66(2):183-194.

7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text rev. Washington, DC: American Psychiatric Association, 2000.

8. Pompili M, Girardi P, Ruberto A, Taterelli R. Toward a new prevention of suicide in schizophrenia. World J Biol Psychiatry 2004;5(4):201-210.

9. Casey DE. Long-term treatment goals: Enhancing healthy outcomes. CNS Spectr 2003;8(11 Suppl 2):26-28.

10. Resnick SG, Fontana A, Lehman AF, Rosenheck RA. An empirical conceptualization of the recovery orientation. Schizophr Res 2005;75(1):119-128.

11. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 2004;161(2 Suppl):1-56.

12. The expert consensus guideline series: treatment of schizophrenia. J Clin Psychiatry 1996;57(Suppl 12B):31.

13. Bellack AS. Skills training for people with severe mental illness. Psychiatr Rehabil 2004;27(4):375-391.

14. Lieberman JA, Stroup TS, McEvoy JP, et al. For the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of an-tipsychotic drugs in people with chronic schizophrenia. N Engl J Med 2005;353(12):1209-1223.

15. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004;161(3):414-425.

16. Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychophar-macology 1996;124(1-2):57-73.

17. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151(6):825-835.

18. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346(1):16-22.

19. Richelson E. Receptor pharmacology of neuroleptics: Relation to clinical effects. J Clin Psychiatry 1999;60(Suppl 10):5-14.

20. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuro-psychopharmacology 1996;14(2):111-123.

21. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997;154(4):457-465.

22. Arvanitis LA, Miller BG, the Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biol Psychiatry 1997;42(4):233-246.

23. Small JG, Hirsch SR, Arvenitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54(6):549-557.

24. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275(1):101-113.

25. Keck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial. Psychopharmacology 1998;140(2):173-184.

26. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20(5):491-505.

27. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical anti-psychotic drug with a unique and robust pharmacology. Neuropsychopharmaco-logy 2003;28(8):1400-1411.

28. Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm 2008;65(5):403-413.

29. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158(3):360-369.

30. Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001;62:Suppl 21:15-18.

31. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50(11):703-714.

32. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997;23(4):583-609.

33. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151-156.

34. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68(11):1751-1762.

35. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The schizophrenia patient outcomes research team (PORT): Updated treatment recommendations 2003. Schizophr Bull 2004;30(2):193-217.

36. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin N Am 2007;30(3):437-452.

37. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128.

38. Remschmidt H. Early-onset schizophrenia as a progressive-deteriorating developmental disorder: Evidence from child psychiatry. J Neural Transm 2002;109:101-117.

39. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52:756-765.

40. Tsuang J, Fong TW. Treatment of patients with schizophrenia and substance abuse disorders. Curr Pharm Des 2004;10(18):2249-2261.

41. Wobrock T, Soyka M. Wobrock T, Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder-reviewing the evidence and clinical research. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(6):1375-1385.

42. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001;50(11):898-911.

43. Meltzer HY. Suicide in schizophrenia, clozapine and adoption of evidence-based medicine. J Clin Psychiatry 2005;60(Suppl 12):47-50.

44. Nilsson E, Lichtenstein P, Cnattingius S, et al. Women with schizophrenia: pregnancy outcome and infant death among their offspring. Schizophr Res 2002;58(2-3):221-229.

45. Diav-Citrin O, Schechtman S, Ornoy S, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005;66(3):317-322.

46. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005;66(4):444-449.

47. Wang JS, Taylor R, Ruan Y, et al. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice and FVB1 (wild type) animals. Neuropsychopharmacology 2004;29(3):551-557.

48. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics 2005;46(5):464-494.

49. Murray-Swank AB, Dixon L. Family psychoeducation as evidence-based practice. CNS Spect 2004;9(12):905-912.

50. Marder SR, Essock SM, Miller AL, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002;28(1): 5-16.

51. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161(8):1334-1349.

52. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601.

53. Love RC, Mackowick M, Carpenter D, Burks EJ. Expert consensus-based medication-use evaluation criteria for atypical antipsychotic drugs. Am J Health Syst Pharm 2003;60:2455-2470.

Was this article helpful?

0 0
Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook

Post a comment